Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Pharmaceutical Technology
JUNE 12, 2025
The drugmaker’s flagship drug semaglutide, known under the brand names Wegovy and Ozempic for obesity and type 2 diabetes treatment respectively, targets the glucagon-like peptide-1 receptor (GLP-1R), a key component of the incretin system. Can pharma tariffs “Make America Manufacture Again”?
Let's personalize your content